

Disclaimer: This report is provided for informational and research purposes only and does not constitute financial, investment, legal, or medical advice. The information contained herein is derived from publicly available sources and automated analyses and may contain errors, omissions, or inaccuracies. No representation or warranty is made regarding the accuracy, completeness, or timeliness of the information. Nothing in this report should be construed as a recommendation to buy, sell, or hold any security or financial instrument. Users are solely responsible for their own research and decisions.

Summary of Selected Trials

NCT ID	Company	Market Cap	Primary Completion	Conditions
NCT05191706	EyePoint Pharmaceuticals, Inc.	\$1,129,217,664	2026-01	Cataract
NCT06615557	VistaGen Therapeutics, Inc.	\$175,754,752	2026-04	Social Anxiety Disorder (SAD)
NCT06122649	Amgen	\$180,967,194,624	2025-02-28	Plaque Psoriasis

NCT ID: NCT05191706

Key details:

Company: EyePoint Pharmaceuticals, Inc.

Market Cap: \$1,129,217,664

Primary Completion Date: 2026-01


Conditions:

Cataract

Trial Status:

Recruiting

Study Timeline




Brief Summary:

A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract


Interventions:

- Dexamethasone (DRUG) - single anterior chamber injection
- Prednisolone Acetate Ophthalmic (DRUG) - topical administration four times a day for 28 days, followed by treatment taper

Historical Phase Transition Probabilities




Research Interest



Company Pipeline

EyePoint Pharmaceuticals, Inc. - Clinical Pipeline



Cataract Market Summary

Source	Market Size (USD)	Year	CAGR
Grand View Research	\$20,000,000,000	2023	5.8%
MarketsandMarkets	\$19,500,000,000	2023	5.5%


Notes: No notes available

Model Used: gemini-2.5-flash-lite

Generated At: 2026-01-25T08:56:36.982227Z

Market Competition

Market Share by Treatment - Cataract



Company	Drug/Treatment
Multiple	Various ophthalmic solutions (post-surgical)
Alcon	Intraocular Lenses (IOLs)
Johnson & Johnson Vision	Intraocular Lenses (IOLs)

Notes: The cataract market is primarily driven by surgical procedures and the associated intraocular lenses (IOLs). Pharmaceutical treatments are mainly supportive post-surgery. Market share for IOLs is estimated. Competition is intense among major ophthalmic device manufacturers.

Model Used: gemini-2.5-flash-lite

Generated At: 2026-01-26T08:49:26.923597Z

NCT ID: NCT06615557

Key details:

Company: VistaGen Therapeutics, Inc.

Market Cap: \$175,754,752

Primary Completion Date: 2026-04


Conditions:

Social Anxiety Disorder (SAD)

Trial Status:

Recruiting

Study Timeline




Brief Summary:

This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-4 and choose to enter the distinct open-label extension phase of the study.


Interventions:

- Fasedienol Nasal Spray (DRUG) - Nasal spray delivered 20 minutes before the PSC
- Placebo Nasal Spray (DRUG) - Nasal spray delivered 20 minutes before the PSC

Historical Phase Transition Probabilities



Research Interest



Sources:

- BIO (2022)


Notes: General pharmaceutical industry averages used as specific data for 'Cataract' is broad.

Model Used: gemini-2.5-flash-lite

Generated At: 2026-01-25T08:19:59.234573Z

Company Pipeline

VistaGen Therapeutics, Inc. - Clinical Pipeline



Social Anxiety Disorder (SAD) Market Summary

Source	Market Size (USD)	Year	CAGR
Grand View Research	\$9,700,000,000	2023	5%
Meticulous Research	\$9,500,000,000	2023	4.8%


Notes: Market size for treatments targeting Social Anxiety Disorder.

Model Used: gemini-2.5-flash-lite

Generated At: 2026-01-25T09:07:15.560208Z

Market Competition

Market Share by Treatment – Social Anxiety Disorder (SAD)



Company	Drug/Treatment
Pfizer	Sertraline (Zoloft)
H. Lundbeck A/S	Escitalopram (Lexapro)
GlaxoSmithKline	Paroxetine (Paxil)
Pfizer	Venlafaxine (Effexor XR)

Notes: Primarily treated with SSRIs and SNRIs. Market share is fragmented due to generic availability.

Model Used: gemini-2.5-flash-lite

Generated At: 2026-01-26T09:06:42.607326Z

NCT ID: NCT06122649

Key details:

Company: Amgen

Market Cap: \$180,967,194,624

Primary Completion Date: 2025-02-28


Conditions:

Plaque Psoriasis

Trial Status:

Completed

Study Timeline




Brief Summary:

The study aims to evaluate the clinical efficacy of oral apremilast 30 mg BID compared with placebo in Chinese participants with moderate to severe PsO


Interventions:

- apremilast (DRUG) - Oral tablet
- Placebo (DRUG) - Oral tablet

Historical Phase Transition Probabilities



Research Interest



Sources:


- Evaluate Vantage (2021)

Notes: General averages for CNS and psychiatric disorders.

Model Used: gemini-2.5-flash-lite

Generated At: 2026-01-25T08:30:05.540145Z

Company Pipeline



Plaque Psoriasis Market Summary


Source	Market Size (USD)	Year	CAGR
Grand View Research	\$22,000,000,000	2023	8.8%
MarketsandMarkets	\$21,500,000,000	2023	8.5%

Notes: Estimates reflect the broader psoriasis market, with plaque psoriasis being the most common type.

Model Used: gemini-2.5-flash-lite

Generated At: 2026-01-25T09:06:03.474130Z

Market Competition



Company	Drug/Treatment
AbbVie	Adalimumab (Humira)
Novartis	Secukinumab (Cosentyx)
Janssen Biotech	Ustekinumab (Stelara)
Eli Lilly	Ixekizumab (Taltz)

Notes: Dominated by biologic therapies (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors). Market is highly competitive with new entrants and biosimil competition.

Model Used: gemini-2.5-flash-lite

Generated At: 2026-01-26T09:04:54.211021Z